Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Marco Galluzzo"'
Autor:
Claudia Paganini, MD, Alfredo Belcastro, MD, Angela Fico, MD, Marina Talamonti, MD, Luca Bianchi, MD, Marco Galluzzo, MD
Publikováno v:
JAAD Case Reports, Vol 53, Iss , Pp 57-59 (2024)
Externí odkaz:
https://doaj.org/article/78e478c67ae54a5487807f10f4ee291d
Autor:
Diego Orsini, Giacomo Caldarola, Annunziata Dattola, Elena Campione, Nicoletta Bernardini, Pasquale Frascione, Clara De Simone, Antonio G. Richetta, Marco Galluzzo, Nevena Skroza, Chiara Assorgi, Emanuele Amore, Gennaro M. Falco, Ruslana Gaeta Shumak, Fabio Artosi, Giulia Maretti, Concetta Potenza, Luca Bianchi, Giovanni Pellacani, Ketty Peris, Claudio Bonifati, Dario Graceffa
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Purpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult
Externí odkaz:
https://doaj.org/article/6ed0bed7541c4a9084145e7ddf8bf2a1
Autor:
Paolo Amerio, Silvia Mariel Ferrucci, Marco Galluzzo, Maddalena Napolitano, Alessandra Narcisi, Anna Levi, Sara Di Fino, Chiara Palladino, Cataldo Patruno, Mariateresa Rossi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1443-1455 (2024)
Abstract Atopic dermatitis (AD) is a highly heterogeneous chronic inflammatory skin disorder that is frequently associated with a plethora of comorbidities. AD is, therefore, considered a systemic disease impacted by a considerable burden and leading
Externí odkaz:
https://doaj.org/article/dca1283cbe5b447288e6cb7dd29a8cc6
Autor:
Marco Galluzzo, Lorenzo Tofani, Sara Spelta, Marina Talamonti, Alessandra Micera, Luca Bianchi, Marco Coassin, Stefano Bonini, Antonio Di Zazzo
Publikováno v:
Skin Health and Disease, Vol 4, Iss 3, Pp n/a-n/a (2024)
Abstract Dupilumab‐associated ocular surface disease is a common clinical sign appearing in patients with atopic dermatitis (AD) just few months after dupilumab treatment start, developing in about 25% of patients. Atopic keratoconjunctivitis (AKC)
Externí odkaz:
https://doaj.org/article/c6b00b465e6648e3b6b5659959358819
Autor:
Giacomo Caldarola, Marco Galluzzo, Nicoletta Bernardini, Elisabetta Botti, Eleonora De Luca, Clara De Simone, Marco Mariani, Gaia Moretta, Sabatino Pallotta, Elena Campione, Ketty Peris
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 2 (2024)
Introduction: Data about the long-term effectiveness of brodalumab could be valuable in assessing patient adherence to treatment and improving psoriasis management. Objective: The aim of our study was to evaluate the drug survival of brodalumab and
Externí odkaz:
https://doaj.org/article/c12852da8d7849db875d715e15d620bf
Publikováno v:
Skin Health and Disease, Vol 4, Iss 1, Pp n/a-n/a (2024)
Abstract Data from real‐world studies and clinical trials have documented the long‐term efficacy and safety of guselkumab in patients with moderate‐to‐severe psoriasis. Limited data are available on the long‐term use of guselkumab in morbid
Externí odkaz:
https://doaj.org/article/898e19ef4da04525902f34a5d9973835
Autor:
Claudia Paganini, MD, Marina Talamonti, MD, Elena Campione, MD, Luca Bianchi, MD, Marco Galluzzo, MD
Publikováno v:
JAAD Case Reports, Vol 39, Iss , Pp 152-154 (2023)
Externí odkaz:
https://doaj.org/article/d03af1b5ee364a2197c69df52eb74b0b
Autor:
Niccolò Gori, Alvise Sernicola, Ersilia Tolino, Maria Mariano, Marco Galluzzo, Gaia Moretta, Rosa Coppola, Andrea D’Alessio, Massimo Sansone, Virginia Maffei, Claudia Paolino, Cristian Ferrao, Lauro Cascia, Paola Addio, Lucia Di Nardo, Andrea Chiricozzi, Ester Del Duca, Antonio Cristaudo, Luca Bianchi, Sabatino Pallotta, Vincenzo Panasiti, Giovanni Pellacani, Concetta Potenza, Ketty Peris
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Objectives The purpose of this study was to analyze the drug survival rate of dupilumab up to 2 years in a large real-world cohort of adult patients affected by moderate/severe atopic dermatitis (AD), and to investigate the clinical, demographic and
Externí odkaz:
https://doaj.org/article/b53505b790e34e229d8174bf1e7755f4
Autor:
Elena Campione, Sara Lambiase, Ruslana Gaeta Shumak, Marco Galluzzo, Caterina Lanna, Gaetana Costanza, Cristiana Borselli, Fabio Artosi, Terenzio Cosio, Lorenzo Tofani, Annunziata Dattola, Francesca Di Daniele, Luca Bianchi
Publikováno v:
Pharmaceuticals, Vol 16, Iss 4, p 526 (2023)
Tildrakizumab is a humanized IgG1κ monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is app
Externí odkaz:
https://doaj.org/article/58dcd009895d4078bba6b0e77dc5001d
Autor:
Antonio Costanzo, Filomena Russo, Marco Galluzzo, Luca Stingeni, Roberta Scuderi, Leonardo Zichichi, Manuela Papini, Luisa Di Costanzo, Andrea Conti, Martina Burlando, Andrea Chiricozzi, Francesca Maria Gaiani, Cristina Mugheddu, Maria Letizia Musumeci, Paolo Gisondi, Stefano Piaserico, Paolo Dapavo, Marina Venturini, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Ketty Peris, Franca Cantoresi, Sara Trevisini, Francesco Loconsole, Annamaria Offidani, Santo Raffaele Mercuri, Viviana Lora, Francesca Prignano, Marta Bartezaghi, Giovanni Oliva, Elisabetta Aloisi, Roberto Orsenigo
Publikováno v:
Acta Dermato-Venereologica, Vol 101, Iss 10 (2021)
Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of respons
Externí odkaz:
https://doaj.org/article/5dd3e7eab6f94b8dbe674e7e25dd7a63